[Evaluation methodology of viral vaccines].
作者信息
Aymard M
机构信息
Faculté de Médecine, Lyon, France.
出版信息
Therapie. 1996 Jul-Aug;51(4):439-43.
PMID:8953827
Abstract
摘要
相似文献
1
[Evaluation methodology of viral vaccines].[病毒疫苗的评估方法]
Therapie. 1996 Jul-Aug;51(4):439-43.
2
Overview of current preclinical testing strategies for viral vaccines.病毒疫苗当前临床前测试策略概述
Dev Biol Stand. 1998;95:19-23.
3
[Principles of controlled trials (author's transl)].
Arzneimittelforschung. 1978;28(11a):2017-9.
4
Risks and benefits of vaccinia-vectored vaccine from the regulatory perspective.从监管角度看痘苗病毒载体疫苗的风险与益处。
Res Virol. 1989 Sep-Oct;140(5):467-9; discussion 487-91. doi: 10.1016/s0923-2516(89)80127-x.
5
Shifting the burden: restructuring the drug review process.转移负担：重塑药物审评流程。
Clin Pharmacol Ther. 1991 Mar;49(3):229-33. doi: 10.1038/clpt.1991.21.
6
Drug evaluation: PSN-9301, a short-acting inhibitor of dipeptidyl peptidase IV.
Curr Opin Investig Drugs. 2007 Apr;8(4):331-7.
7
MRI for development of disease-modifying osteoarthritis drugs.
NMR Biomed. 2006 Oct;19(6):669-80. doi: 10.1002/nbm.1071.
8
Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases.用于传染病的颗粒介导DNA疫苗的临床前和临床进展
Methods. 2006 Sep;40(1):86-97. doi: 10.1016/j.ymeth.2006.05.022.
9
[Drug screening and evaluation. Directions and execution].[药物筛选与评价。指导与实施]
Fortschr Med. 1977 Mar 10;95(10):601-2.
10
Drug evaluation: rivoglitazone, a new oral therapy for the treatment of type 2 diabetes.药物评价：罗格列酮，一种用于治疗2型糖尿病的新型口服疗法。
Curr Opin Investig Drugs. 2007 Apr;8(4):338-44.
Zotero 插件